Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of Disease

Figure 1

(a) Mean GH levels in basal condition, evaluated as the mean of at least three consecutive samples, in patients of group A (i.e., GH nadir ≥ 0.4 mcg/L, upper) and group B (i.e., GH nadir < 0.4 mcg/L, lower). Patients of group B showed mean GH levels at long-term follow-up (phase 3) significantly lower than at the time of remission (phase 1), whereas no difference was observed in group A. versus phase 1. Values are expressed as mean ± SEM. (b) Mean GH nadir, defined as the lowest GH value at any time after glucose administration (2 h-OGTT), in patients of group A (i.e., GH nadir ≥ 0.4 mcg/L, upper) and group B (i.e., GH nadir < 0.4 mcg/L, lower). Patients of group B showed mean GH nadir levels atlong-term follow-up (phase 3) and at the time of the last assessment available with the GH assay standardized to IS 80/505 (phase 2) significantly lower than at the time of remission (phase 1), whereas the decrease did not reach statistical significance in patients of group A. versus phase 1. Values are expressed as mean ± SEM.

(a)

(b)